BioSpace News Archive

Guerbet LLC USA, the U.S. affiliate of the global specialist in contrast media products and solutions for diagnostic and interventional imaging, is pleased to support the sixth annual Melanoma Research Foundation Gala in Philadelphia, PA.

Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that it has initiated its MicroPine Phase III program with the first patient enrolled in its CHAPERONE study.

Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration company, today announced advancements on several fronts for its key asset, QBM-001, in the treatment of pediatric minimally verbal autism (PMVA), a rare autism spectrum disorder (ASD) for which no effective treatment currently exists.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a Type II variation to the European Medicines Agency (EMA) seeking approval of ERLEADA®(apalutamide) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC), regardless of extent of disease or prior docetaxel treatment history.

ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced the successful completion of its single ascending dose (SAD) study testing the first-in-class therapeutic antibody ASLAN004 in healthy volunteers, and the updated data from the second part of the study that tested a subcutaneous formulation of ASLAN004.

Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced positive data from the ongoing patients in the Phase Ib study of its HER-Vaxx cancer vaccine was presented at the prestigious American Society of Clinical Oncology (ASCO) annual meeting in Chicago Illinois, USA 31 May to 3 June 2019.

Dr. Reddy’s Laboratories Limited announced that its Annual Report on Form 20-F, containing its annual consolidated financial statements for the fiscal year ended March 31, 2019 was filed with the United States Securities and Exchange Commission on June 3, 2019.

Nominations for the Future Digital Awards for Technology & Innovation 2019 are now open.

Funding will support this registration study and rapid global availability of the vaccine against Chikungunya

Innovative CME program presents renowned multi-specialty aesthetic practitioners